We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Jz Capital Partners Limited | LSE:JZCP | London | Ordinary Share | GG00BT3MVL31 | ORD NPV |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 205.00 | 190.00 | 220.00 | - | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Investors, Nec | 16.34M | 1.61M | 0.0238 | 86.13 | 138.73M |
Date | Subject | Author | Discuss |
---|---|---|---|
12/5/2015 08:39 | Starting to reduce discout to nav with vield (subject to exchange rates) in the region of 4.8%. There will be an analyst and investor presentation to discuss JZCP's recent financial performance and portfolio developments at 11:30 UK time today at FTI Consulting, 200 Aldersgate, Aldersgate Street, London EC1A 4HD. It can be accessed by dialing +44 (0)20 3427 1917 (UK) or +1 718 971 5738 (US) with the participant access code 3705203. A playback facility will be available two hours after the conference call concludes. This facility may be accessed by dialing +44 (0)20 3427 0598 (UK) or +1 347 366 9565 (US) with the participant access code 3705203. | pugugly | |
11/3/2015 17:50 | I hadn't heard of this one until I found this write up: hxxp://wertartcapita Interesting. | greasynut | |
21/7/2014 20:13 | please see in news header below chart on top | jaws6 | |
21/7/2014 18:42 | Convertible loan stock prospectus announcement today. Interesting. Anyone got a copy of the prospectus please? | topvest | |
19/6/2014 15:48 | some cross trades going at 443.5 | jaws6 | |
18/6/2014 22:32 | Article was four weeks ago but seems not to have been spotted yet in the UK. To paraphrase, it says that Factor Energia (JZCP 65%) is on the market for sale, with a price tag of around Euros 200m. JZCP has instructed Lazards and there has been a fair amount of interest. If achieved (that may of course be a big 'if'), Euros 200m would = about $177m for JZCP's 65% interest. Valued in latest accounts at $92.2m. Increase in NAV $85m = £50m = 77p/share approx based on 65m shares in issue. | pldazzle | |
06/5/2014 11:18 | Yes, agreed - a good solid investment. More than happy to hold this. | topvest | |
06/5/2014 08:36 | Current NAV of $10.25, or approximately £6.04 at today's exchange rates. Unloved and under the radar, but with a 27% discount to NAV and excellent performance of underlying investments this looks like a bargain in anticipation of a $/£ recovery over the next couple of years. | m1das_touch | |
25/9/2013 13:09 | I assume that the weaker dollar is eroding the sterling value here. Looking to buy in small quantities... | pyemckay | |
06/11/2011 21:01 | An excellent spot, many thanks for posting! And yes, a big uplift on the valuation. Is this the deal referred to in the interims, I wonder: "As expected, the upheaval in the capital markets has made realisations challenging, though we hope to have some good news within the next year." | courant | |
05/11/2011 11:40 | There's many a slip... but IF this article is anywhere near accurate, and IF the deal comes to fruition, it could mean a bonanza for JZCP: Metalmark Capital is using $355 million in leverage to acquire a unit of Wound Care Holdings LLC from fellow private equity firm Jordan & Co. in a transaction valued at more than $500 million, according to sources familiar with the matter. According to a Sept. 30 announcement of the transaction, whose financial terms were not disclosed, New York-based Metalmark, a private equity unit of Citi Global Markets Inc., plans to merge it with portfolio company National Healing Corp., a Boca Raton, Fla.-based wound care provider. Jefferies & Co., RBC Capital Markets LLC and BMO Capital Markets Corp. are bookrunners on the loan, said one source. Wound Care Holdings, formed in 2006, consists of two units: Diversified Clinical Services Inc., an outsourced manager of on-site hospital wound care clinics; and Sechrist Industries Inc., a manufacturer of hyperbaric chambers and varied medical equipment. Jordan is selling Diversified Clinical Services but not Sechrist. Jordan did not respond to a request for comment. "Wound care and medical technology products place well in an environment like this," said a banker familiar with the deal. An aging population, combined with the rise in diabetes, cardiovascular disease and obesity, has created a $14 billion global wound care industry, said the release. Standard & Poor's Leveraged Commentary & Data said the senior secured loan comprises a $30 million, five-year revolver, a $250 million, six-year first-lien term loan and a $75 million, second-lien term loan. Metalmark acquired a controlling stake in National Healing in 2008 for an undisclosed amount. Scale Venture Partners was a prior investor in 2005 and retained a stake. CapitalSource Finance LLC provided the financing to Metalmark for that transaction. Metalmark also recently exited shipping foam company Tegrant Corp., which it sold to packaging conglomerate Sonoco Products Co. for $550 million, according to an Oct. 10 announcement. Moelis & Co. and Jefferies & Co. are Diversified Clinical Services' financial advisers. SNR Denton US LLP and Hogan Lovells US LLP provided legal counsel. Read more: Metalmark taps $355M debt for Wound Care purchase - The Deal Pipeline(SAMPLE CONTENT: NEED AN ID?) - - - - - - - At 30 August 2011. per the recent interim report, JZCP valued its interest in Diversified Clinical at $42.9m. I believe JZCP holds 22.2% of the equity, plus a combination of 13% and 15% Preferred Shares. | pldazzle | |
18/10/2011 19:42 | Yes, think this is good value long term. Think they will generally make good investments and generate good long term returns. | topvest | |
18/10/2011 09:08 | Results look ok and I like the comment about share buy backs. Still just looking though many deeply discounted shares to chose from and some seem to be under further pressure. | praipus | |
18/10/2011 08:58 | No but I'm looking at it again. | davebowler | |
13/10/2011 10:23 | Still here davebowler? | praipus | |
29/4/2010 10:13 | 35% discount to NAV | davebowler | |
24/11/2009 13:37 | NAV c.£4 per share. | davebowler | |
16/6/2009 13:33 | Pleased I bought at 17p in early March, now 46p. Is there anything more to wait for? | robertsbb0 | |
21/4/2009 11:21 | Hopefully good news on the way. | robizm | |
16/4/2009 17:33 | 150% uplift in a month. cant complain. hope they can extend the zero's or issue new ones for 7 yrs time | robizm | |
19/3/2009 10:40 | a significant portion of the listed portfolio couldn't be sold due to "tie in's" (is that possible with listed equities?) Owston, yes, when a company IPOs, existing holders are locked in for a period which can be up to three years (in the UK, anyway). There are waivers, such as if another insti will take on the holding under the same conditions. For me this is on the back burner now: I'm unlikely to buy but no advice intended! | jonwig | |
19/3/2009 10:38 | Just had another look at the February update....... 1) It clearly says that "liquid" assets represent 43% of the portfolio and the portfolio is valued at $473m. as at 31/12/08 that means that $203.4m was "liquid" - more than enough to cover the ZDP repayment and Hedge position. 2) If we assume that there has been a further decline of 20% in total assets then that would leave about $400m and assuming that the liquid portfolio is not adversely affected relative to the illiquid investments then they would still have around $172m which is not far off enough to repay the ZDP's and the hedge. Any thoughts? | owston |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions